Coia Dulsat

Barcelona

Staff Writer at BioWorld

Staff Writer at BioWorld Science

Featured in: Favicon

bioworld.com

Articles

Lipid uptake drives immune evasion in high-grade serous ovarian cancer

2 days ago | bioworld.com | Coia Dulsat

Home » Lipid uptake drives immune evasion in high-grade serous ovarian cancer BioWorld briefs for May 12, 2025. BioWorld MedTech briefs for May 12, 2025. After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,... Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategyâ€™s ultimate clinical...
ADPD 2025: Novel treatment modalities in neurodegenerative disorders

1 month ago | bioworld.com | Coia Dulsat

ADPD 2025: Novel treatment modalities in neurodegenerative disordersThe current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease (PD) and anti-tau therapies, which are primarily used in AD but are also being explored for PD.
ADPD 2025: Novel treatment modalities in neurodegenerative disorders

1 month ago | bioworld.com | Coia Dulsat

Neurology/psychiatricADPD 2025: Novel treatment modalities in neurodegenerative disordersThe current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease (PD) and anti-tau therapies, which are primarily used in AD but are also being explored for PD.
ADPD 2025: Unfolding the field of neurolipidomics

1 month ago | bioworld.com | Coia Dulsat

Home » ADPD 2025: Unfolding the field of neurolipidomics BioWorld briefs for April 4, 2025. BioWorld MedTech briefs for April 4, 2025. At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald... At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...
ADPD 2025: Unfolding the field of neurolipidomics

1 month ago | bioworld.com | Coia Dulsat

Home » ADPD 2025: Unfolding the field of neurolipidomics BioWorld briefs for April 4, 2025. BioWorld MedTech briefs for April 4, 2025. At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald... Although the causes of polycystic ovary syndrome (PCOS) are unclear, researchers know this condition leads to endometrial dysfunction in women who have hormonal...
ADPD 2025: Emerging strategies fueling Alzheimer’s disease research

1 month ago | bioworld.com | Coia Dulsat

Home » ADPD 2025: Emerging strategies fueling Alzheimer’s disease research BioWorld briefs for April 2, 2025. BioWorld MedTech briefs for April 2, 2025. The renal denervation patent wars are now in full swing, with Medtronic plc and Recor Medical LLC landing the first blow in this chapter of the med tech patent... At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...
ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

1 month ago | bioworld.com | Coia Dulsat

Neurology/psychiatricADPD 2025: Unlocking GLP-1's potential in neurodegenerationAt the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in glucagon-like peptide-1 (GLP-1) research, delivered a plenary lecture focused on the role of GLP-1 receptor agonists, such as semaglutide, in attenuating neuroinflammation and neurodegeneration. BioWorld Science Conferences Neurology/psychiatric
Unlocking early genetic drivers of stomach cancer

1 month ago | bioworld.com | Coia Dulsat

CancerUnlocking early genetic drivers of stomach cancerResearch published online in Nature on March 19, 2025, closely examines the changes occurring in the gastric epithelium during the progression toward cancer development. Certain mutations that occur in normal, nonreproductive cells over time can make these cells more prone to becoming cancerous later.
Hepatic stellate cells shape and control liver function

1 month ago | bioworld.com | Coia Dulsat

Home » Hepatic stellate cells shape and control liver function BioWorld briefs for March 19, 2025. BioWorld MedTech briefs for March 19, 2025 U.S. President Donald Trump touched off a not-uncommon flurry of puzzlement and outrage when, during his speech to Congress on March 4, he referred to an example... In another real-life episode of “sponsor beware,” the owners of a clinical research facility pleaded guilty March 10 in U.S. district court to fraud charges...
Hepatic stellate cells shape and control liver function

1 month ago | bioworld.com | Coia Dulsat

Home » Hepatic stellate cells shape and control liver function BioWorld briefs for March 18, 2025. BioWorld MedTech briefs for March 18, 2025 U.S. President Donald Trump touched off a not-uncommon flurry of puzzlement and outrage when, during his speech to Congress on March 4, he referred to an example... In another real-life episode of “sponsor beware,” the owners of a clinical research facility pleaded guilty March 10 in U.S. district court to fraud charges...